ASCO GU 2019: Pembrolizumab Plus Axitinib Extended Overall Survival and Progression-Free Survival Versus Current Standard Treatment for Advanced Kidney Cancer
Results from the randomized, phase III KEYNOTE-426 clinical trial show that first-line therapy with a…